未登录

Y

Yidong Zhou

Zhejiang Chinese Medical University

H指数:12

被引数:557

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Finerenone in IgA nephropathy: real-world 12-month propensity-matched cohort demonstrating proteinuria reduction, eGFR preservation, and safety profile

非奈利酮在IgA肾病中的应用：真实世界12个月倾向性匹配队列研究显示蛋白尿减少、估算肾小球滤过率保留及安全性特征

IF3

2026-04-190

OA

Long non-coding RNA in hepatocellular carcinoma: mechanistic insights and therapeutic perspectives

长链非编码RNA在肝细胞癌中的机制见解和治疗前景

Cellular Oncology

IF4.8

2025-11-040

OAAI

A Multi-Omics-Based Prognostic Model for Elderly Breast Cancer by Machine Learning: Insights From Hypoxia and Immunity of Tumor Microenvironment

基于多组学的机器学习老年乳腺癌预后模型：肿瘤微环境缺氧与免疫的启示

Clinical Breast Cancer

IF2.5

2025-04-150

OAAI

The emerging role of glycolysis and immune evasion in ovarian cancer

糖酵解和免疫逃避在卵巢癌中的新兴作用

CANCER CELL INTERNATIONAL

IF6

2025-03-050

OAAI

A multi-centre, randomised trial for diagnostic efficacy of the automatic breast volume scanner ultrasound for breast cancer screening in China

FRONTIERS IN ONCOLOGY

IF3.3

2025-01-210

OAAI

Development and validation of a model and nomogram for breast cancer diagnosis based on quantitative analysis of serum disease-specific haptoglobin N-glycosylation

JOURNAL OF TRANSLATIONAL MEDICINE

IF7.5

2024-04-041

OAAI

Breast cancer pre-clinical screening using infrared thermography and artificial intelligence: a prospective, multicentre, diagnostic accuracy cohort study

INTERNATIONAL JOURNAL OF SURGERY

IF10.1

2023-09-042

OAAI

Identification of genetic and immune signatures for the recurrence of HER2-positive breast cancer after trastuzumab-based treatment

BREAST CANCER RESEARCH AND TREATMENT

IF3

2023-04-212

PRE

Antidiarrheal prophylaxis with loperamide for patients with lymph node-negative (N0) or micrometastatic (N1mi), HER2-positive breast cancer who received adjuvant pyrotinib plus nab-paclitaxel: a randomized sub-study of PHAEDRA

CANCER RESEARCH

IF16.6

2023-03-010

PRE

Molecular imaging of HER2 expression in breast cancer patients using a novel peptide-based tracer 99mTc-HP-Ark2: a pilot study

JOURNAL OF TRANSLATIONAL MEDICINE

IF7.5

2023-01-115

OAAI

Rationale and design of a phase II trial of pyrotinib in combination with nab-paclitaxel as adjuvant therapy for N0/N1mi, HER2+early breast cancer (PHAEDRA)

IF3.4

2022-03-140

OAAI

Long noncoding RNA AFAP1-AS1 promotes tumor progression and invasion by regulating the miR-2110/Sp1 axis in triple-negative breast cancer

长链非编码RNA AFAP1-AS1通过调控miR-2110/Sp1轴促进三阴性乳腺癌的进展和侵袭

CELL DEATH & DISEASE

IF9.6

2021-06-1833

OAAI

Cancer-derived exosomal miR-7641 promotes breast cancer progression and metastasis

CELL COMMUNICATION AND SIGNALING

IF8.9

2021-02-2256

OAAI

Genetic factors associated with cancer racial disparity - an integrative study across twenty-one cancer types

MOLECULAR ONCOLOGY

IF4.5

2020-09-247

OAAI

miR-452 Reverses Abnormal Glycosylation Modification of ERα and Estrogen Resistance in TNBC (Triple-Negative Breast Cancer) Through Targeting UGT1A1

FRONTIERS IN ONCOLOGY

IF3.3

2020-08-2611

OAAI

Comparison of lymph node ultrasound and pathological characteristics of breast cancer patients with positive and negative sentinel lymph node

CANCER RESEARCH

IF16.6

2020-02-150

PRE

MicroRNA-320a suppresses tumor cell growth and invasion of human breast cancer by targeting insulin-like growth factor 1 receptor

ONCOLOGY REPORTS

IF3.9

2018-06-207

OAAI

Tumoral expression of drug and xenobiotic metabolizing enzymes in breast cancer patients of different ethnicities with implications to personalized medicine

SCIENTIFIC REPORTS

IF3.9

2017-07-0647

OAAI